For your patients who wake up at least 2 times a night to urinate because of nocturia due to nocturnal polyuria,1

make NOCTIVA THE ONE

Specifically engineered to provide the lowest effective and safe dose of desmopressin on the market.2

See Efficacy Data

For your patients who wake up at least 2 times a night to urinate because of nocturia due to nocturnal polyuria,1

make NOCTIVA THE ONE

Specifically engineered to provide the lowest effective and safe dose of desmopressin on the market.2

See Efficacy Data
NOCTIVATM (desmopressin acetate) 0.83 mcg Nasal Spray set on counter

More hours of uninterrupted sleep3

Significantly reduced nocturnal urine production3

Can work on the first night3

Significantly reduced the number of nocturnal voids1

Nocturia impacts millions of patients4,5

Nocturia leads to insufficient or low-quality sleep, which in turn can lead to impaired cognitive and physical function— especially if the first 4 hours aren’t restful.6-9

Why Nocturia Matters

THE ONE designed to optimize delivery via a unique nasal spray1,3

NOCTIVA™ (desmopressin acetate) Nasal Spray pharmacokinetics allow for the use of the lowest dose of desmopressin on the market.2

Consistent absorption and predictable pharmacokinetics1,10

Requires no behavior modifications or fluid restrictions10,11

Absorbed in 15 to 45 minutes1

Clears in 4 to 6 hours1

THE SIMPLICITY OF1

ONE
spray

ONE
nostril

ONE
time a night

And it can work
THE FIRST NIGHT3
NOCTIVATM (desmopressin acetate) 0.83 mcg Nasal Spray held in hand
NOCTIVATM (desmopressin acetate) Nasal Spray with co-pay card which ensures patients pay no more than $40

NOCTIVA is accessible

Co-pays are $40 or less* for patients with commercial insurance, Medicare Part D, and VA/Tricare/Medicaid.

Download a co-pay card

*Co-pay may exceed $40 for patients with federally funded insurance coverage.

Mike, a patient getting more sleep at night with NOCTIVATM (desmopressin acetate) Nasal Spray
I noticed a difference the first time I used NOCTIVA. The first night, instead of waking up 4 to 5 times, I woke up only once. By the third and fourth night on NOCTIVA, I slept through the night without waking up once!
– Mike, 60, actual NOCTIVA patient
Individual results may vary. Results not guaranteed.

Take action

Many of your patients could be waking up tonight because of nocturia due to nocturnal polyuria. With NOCTIVA, you could reduce its impact.1

Take action

Many of your patients could be waking up tonight because of nocturia due to nocturnal polyuria. With NOCTIVA, you could reduce its impact.1

Next up

See the impact nocturia has on millions of patients.4,5

Nocturia Matters
REFERENCES

1. NOCTIVA [package insert]. Chesterfield, MO: Avadel Specialty Pharmaceuticals, LLC; 2017. 2. US Food and Drug Administration. Orange Book Noctiva. https://www.acessdata.fda.gov/scripts/cder/ob/search_product.cfm. Accessed August 13, 2018. 3. Data on file. Avadel Specialty Pharmaceuticals, LLC. 4. Fitzgerald MP, Litman HJ, Link CL, McKinlay JB; BACH Survey Investigators. The association of nocturia with cardiac disease, diabetes, body mass index, age and diuretic use: results from the BACH survey. J Urol. 2007;177(4):1385-1389. 5. Population distribution by age. Kaiser Family Foundation website. https://www.kff.org/other/state-indicator/distribution-by-age. Accessed August 13, 2018. 6. Ancoli-Israel S, Bliwise DL, Nørgaard JP. The effect of nocturia on sleep. Sleep Med Rev. 2011;15(2):91-97. 7. Cappuccio FP, Cooper D, D’Elia L, Strazullo P, Miller MA. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Eur Heart J. 2011;32(12):1484-1492. 8. Kupelian V, Wei JT, O’Leary MP, Nørgaard JP, Rosen RC, McKinlay JB. Nocturia and quality of life: results from the Boston Area Community Health Survey. Eur Urol. 2012;61(1):78-84. 9. Stanley N. The underestimated impact of nocturia on quality of life. Eur Urol. 2005;4(7)(suppl):17-19. 10. Cohn JA, Kowalik CG, Reynolds WS, et al. Desmopressin acetate nasal spray for adults with nocturia. Expert Rev Clin Pharmacol. 2017;10(12):1281-1293. 11. Kaminetsky J, Fein S, Dmochowski R, et al. Efficacy and safety of SER120 nasal spray in patients with nocturia: pooled analysis of 2 randomized, double-blind, placebo controlled, phase 3 trials. J Urol. 2018;200(3):604-611.

Order Samples
INDICATION AND IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

WARNING: HYPONATREMIA

See full prescribing information for complete boxed warning.

  • NOCTIVA can cause hyponatremia, which may be life-threatening if severe.
  • NOCTIVA is contraindicated in patients at increased risk of severe hyponatremia, such as patients with excessive fluid intake, illnesses that can cause fluid or electrolyte imbalances, and in those using loop diuretics or systemic or inhaled glucocorticoids.
  • Ensure serum sodium is normal before starting or resuming NOCTIVA. Measure serum sodium within seven days and approximately one month after initiating therapy or increasing the dose, and periodically during treatment. More frequently monitor serum sodium in patients 65 years of age and older and in patients at increased risk of hyponatremia.
  • If hyponatremia occurs, NOCTIVA may need to be temporarily or permanently discontinued.
Indications and usage

NOCTIVA is a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void.

Limitation of Use: Not studied in patients younger than 50 years of age.

Contraindications
  • Hyponatremia or a history of hyponatremia
  • Polydipsia
  • Primary nocturnal enuresis
  • Concomitant use with loop diuretics or systemic or inhaled glucocorticoids
  • Estimated glomerular filtration rate below 50 mL/min/1.73 m2
  • Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
  • During illnesses that can cause fluid or electrolyte imbalance
  • New York Heart Association (NYHA) Class II-IV congestive heart failure
  • Uncontrolled hypertension
Warnings and Precautions
  • Fluid retention: Not recommended in patients at risk of increased intracranial pressure or history of urinary retention. Monitor volume status in patients with NYHA Class I congestive heart failure.
  • Nasal conditions: Discontinue in patients with concurrent nasal conditions that may increase absorption, until resolved.
Adverse Reactions

Common adverse reactions in clinical trials (incidence >2%) included nasal discomfort, nasopharyngitis, nasal congestion, sneezing, hypertension / blood pressure increased, back pain, epistaxis, bronchitis and dizziness.

Drug Interactions

Monitor serum sodium more frequently when NOCTIVA is concomitantly used with drugs that may cause water retention and increase the risk for hyponatremia (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, nonsteroidal anti-inflammatories, lamotrigine and carbamazepine).

Use in Specific Populations
  • Pregnancy: Use of NOCTIVA is not recommended.
  • Pediatric: Do not use NOCTIVA for primary nocturnal enuresis in children.

To report SUSPECTED ADVERSE REACTIONS, contact Avadel at 1-877-638-4579 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATION AND IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

WARNING: HYPONATREMIA

See full prescribing information for complete boxed warning.

  • NOCTIVA can cause hyponatremia, which may be life-threatening if severe.
  • NOCTIVA is contraindicated in patients at increased risk of severe hyponatremia, such as patients with excessive fluid intake, illnesses that can cause fluid or electrolyte imbalances, and in those using loop diuretics or systemic or inhaled glucocorticoids.
  • Ensure serum sodium is normal before starting or resuming NOCTIVA. Measure serum sodium within seven days and approximately one month after initiating therapy or increasing the dose, and periodically during treatment. More frequently monitor serum sodium in patients 65 years of age and older and in patients at increased risk of hyponatremia.
  • If hyponatremia occurs, NOCTIVA may need to be temporarily or permanently discontinued.
Indications and usage

NOCTIVA is a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void.

Limitation of Use: Not studied in patients younger than 50 years of age.

Contraindications
  • Hyponatremia or a history of hyponatremia
  • Polydipsia
  • Primary nocturnal enuresis
  • Concomitant use with loop diuretics or systemic or inhaled glucocorticoids
  • Estimated glomerular filtration rate below 50 mL/min/1.73 m2
  • Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
  • During illnesses that can cause fluid or electrolyte imbalance
  • New York Heart Association (NYHA) Class II-IV congestive heart failure
  • Uncontrolled hypertension
Warnings and Precautions
  • Fluid retention: Not recommended in patients at risk of increased intracranial pressure or history of urinary retention. Monitor volume status in patients with NYHA Class I congestive heart failure.
  • Nasal conditions: Discontinue in patients with concurrent nasal conditions that may increase absorption, until resolved.
Adverse Reactions

Common adverse reactions in clinical trials (incidence >2%) included nasal discomfort, nasopharyngitis, nasal congestion, sneezing, hypertension / blood pressure increased, back pain, epistaxis, bronchitis and dizziness.

Drug Interactions

Monitor serum sodium more frequently when NOCTIVA is concomitantly used with drugs that may cause water retention and increase the risk for hyponatremia (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, nonsteroidal anti-inflammatories, lamotrigine and carbamazepine).

Use in Specific Populations
  • Pregnancy: Use of NOCTIVA is not recommended.
  • Pediatric: Do not use NOCTIVA for primary nocturnal enuresis in children.

To report SUSPECTED ADVERSE REACTIONS, contact Avadel at 1-877-638-4579 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.